An Emerging Markets Sponsored Commentary
It's that last line that we covet in all the companies we’re asked to cover. The algorithm is simple:
Hot Market + Performance = Favorable Valuations.
And we believe that the intersection of Health Care and Artificial Intelligence is the first half of that formula.
It appears Nvidia does too. Check out this simple declaration from their corporate site:
Healthcare demands new computing paradigms to meet the need for personalized medicine, next-generation clinics, enhanced quality of care, and breakthroughs in biomedical research to treat disease. With NVIDIA, healthcare institutions can harness the power of AI and high-performance computing (HPC) to define the future of medicine.
Enter
Obviously there is a massive difference in the size of these two equities with similar interests in leveraging A.I. to improve human health care outcomes. But there is also a vast difference between HEALWELL and a slate of A.I. companies who will never earn a buck, who are chasing A.I. market sympathy or hoping that their tech is someday marketable and sellable.
It is worth noting that HEALWELL posted revenue of
Sure, that rev number is Nvidia’s proverbial bar bill but it’s still a massive number for a Company at HEALWELL’S station in the market and for a company still widely unknown by the market at large.
But for how long?
If the revenue trend continues, analysts, partners, and market interests may follow. That’s not original thinking, of course. That’s just the way the market works.
Post material revs and showing a durable business model in an expanding market, produces favorable results.
Like with Nvidia.
Meanwhile, HEALWELL has been busy beside all that revenue. Real moves that portend well for the Company.
A recent release from HEALWELL doesn’t declare more revenue but it certainly speaks to massive opportunities for the Company:
HEALWELL AI Announces New Commercial Agreements with
Here’s the link for the full read.
The bullets from the release are compelling:
- HEALWELL AI has signed services agreements with both
WELL Health USA andU.S. basedCircle Medical Technologies Inc. , which expands its footprint in theU.S. and will enableU.S. healthcare providers with a suite of artificial intelligence (AI) powered preventative care solutions.
- HEALWELL’s
Pentavere Research Group Inc. has partnered with WELL Health USA’sCRH Medical to accessU.S. clinical data to gain insights in supporting patients who are dealing with Inflammatory Bowel Disease and other gastrointestinal conditions. Through the agreement, Pentavere’s DARWEN™ AI platform will analyze over 200,000 US patients, in a secure and compliant manner across 21 states to understand the real-world dynamics between biologic prescribing and treatment outcomes.
- HEALWELL’s
Khure Health will integrate its proprietary AI platform with Circle Medical’s electronic medical record system, expanding its footprint to over 30 US states. Khure’s AI will screen for and flag individual patients whom the healthcare practitioner might consider for further investigation for potential earlier diagnosis of rare disease.
This release has THREE separate commercial agreements that are established to potentially drive revenues.
And HEALWELL is certainly following the leader, acquiring and developing potentially lucrative Healthcare A.I. technology and commercializing it at a rapid clip of its own.
About The Emerging Markets Report:
The Emerging Markets Report is owned and operated by
For more informative reports such as this, please sign up at https://emergingmarketsconsulting.com/alerts/
Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.
We may purchase Securities of the
EMC has been paid
https://emergingmarketsconsulting.com/disclaimer/
Emerging Markets Consulting, LLC
390 North Orange Ave STE 2300
E-mail: jamespainter@emergingmarketsllc.com
Web: www.emergingmarketsllc.com
Source:
2024 GlobeNewswire, Inc., source